Payment overview · 2025
General Payments
$470.75
25 reported records · 14 companies
Healthcare provider profile · identity verified
Jeffrey Moore, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STEPHENVILLE, TX · NPI 1023014008
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Moore, M.D. received $470.75 in general payments during 2025 across 25 reported records.
Exact Sciences Corporation accounted for 19.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 259 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $90.91 | 19.3% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $55.24 | 11.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.48 | 10.7% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $41.28 | 8.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.68 | 8.2% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.99 | 7.4% | 2 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $32.71 | 7.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.22 | 5.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.63 | 4.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.14 | 4.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.78 | 3.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.08 | 3.2% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $14.02 | 3.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $13.59 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $470.75 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $55.24 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $54.38 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $50.48 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $41.28 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $36.53 | 2 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $32.71 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
259 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 749 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 678 | 139 |
| Atorvastatin Calcium | Atorvastatin Calcium | 609 | 146 |
| Gabapentin | Gabapentin | 530 | 102 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 502 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 495 | 107 |
| Furosemide | Furosemide | 391 | 91 |
| Lisinopril | Lisinopril | 384 | 91 |
| Potassium Chloride | Potassium Chloride | 371 | 74 |
| Losartan Potassium | Losartan Potassium | 367 | 88 |
| Sertraline Hcl | Sertraline Hcl | 315 | 63 |
| Alprazolam | Alprazolam | 297 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 293 | 67 |
| Tramadol Hcl | Tramadol Hcl | 270 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 264 | 63 |
| Eliquis | Apixaban | 259 | 36 |
| Prednisone | Prednisone | 216 | 86 |
| Metformin Hcl | Metformin Hcl | 212 | 50 |
| Omeprazole | Omeprazole | 191 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 190 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 176 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 174 | 46 |
| Lorazepam | Lorazepam | 165 | 25 |
| Montelukast Sodium | Montelukast Sodium | 154 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 43 |
| Simvastatin | Simvastatin | 135 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 130 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 35 |
| Carvedilol | Carvedilol | 123 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 29 |
| Famotidine | Famotidine | 114 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 37 |
| Glipizide | Glipizide | 108 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 19 |
| Celecoxib | Celecoxib | 96 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 93 | 20 |
| Clonazepam | Clonazepam | 92 | 16 |
| Cefuroxime | Cefuroxime Axetil | 89 | 53 |
| Donepezil Hcl | Donepezil Hcl | 88 | 19 |
| Cefdinir | Cefdinir | 87 | 66 |
| Allopurinol | Allopurinol | 86 | 19 |
| Atenolol | Atenolol | 80 | 20 |
| Buspirone Hcl | Buspirone Hcl | 80 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 16 |
| Ezetimibe | Ezetimibe | 75 | 19 |
| Trazodone Hcl | Trazodone Hcl | 73 | 15 |
| Meloxicam | Meloxicam | 71 | 18 |
| Ozempic | Semaglutide | 71 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 21 |
| Pregabalin | Pregabalin | 68 | 11 |
| Temazepam | Temazepam | 68 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 46 |
| Ondansetron Odt | Ondansetron | 60 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 59 | 22 |
| Warfarin Sodium | Warfarin Sodium | 59 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 15 |
| Methocarbamol | Methocarbamol | 56 | suppressed |
| Amoxicillin | Amoxicillin | 52 | suppressed |
| Irbesartan | Irbesartan | 52 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 12 |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 46 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 13 |
| Synthroid | Levothyroxine Sodium | 45 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 13 |
| Spironolactone | Spironolactone | 40 | 11 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Diazepam | Diazepam | 38 | 11 |
| Gemfibrozil | Gemfibrozil | 37 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Budesonide | Budesonide | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 33 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Ramipril | Ramipril | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 11 |
| Loperamide | Loperamide Hcl | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 20 |
| Cephalexin | Cephalexin | 24 | 18 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Jantoven | Warfarin Sodium | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Premarin | Estrogens, Conjugated | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Acyclovir | Acyclovir | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 14 | 13 |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Phenelzine Sulfate | Phenelzine Sulfate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 12 |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Victoza 2-Pak | Liraglutide | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Dicloxacillin Sodium | Dicloxacillin Sodium | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $470.75 · 25 records | Exact Sciences Corporation | ABRYSVO, AUSTEDO XR, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FARXIGA, INGREZZA, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JATENZO, Jornay PM, KEVEYIS, KRYSTEXXA, PREVNAR 20, TZIELD, The Cologuard Plus Collection Kit, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error